Archive · 10 Nov 2025
Australian Scientists Explore Bacteria as Potential 'Living Medicines' for Cancer Treatment
Scientists are exploring using tiny living things called bacteria as a new way to fight cancer.
Some bacteria are good at finding and growing inside tumors, which are like unwanted lumps in the body.
These bacteria can also help your body's defense system, called the immune system, to find and attack cancer cells.
Scientists are changing these bacteria to carry medicines directly to the tumor or to teach your immune system how to recognize and fight the cancer.
This is like having smart, tiny helpers that can go straight to the problem area.
While this idea, called 'bugs as drugs,' is still new and needs more testing to be safe and effective, it could lead to different ways to treat cancer in the future.
Researchers are working to make sure these bacterial medicines can be controlled and don't cause harm to healthy parts of the body.
Australian scientists are researching the use of genetically engineered bacteria as 'living medicines' to treat cancer.
Certain bacteria naturally target solid tumors, which can then be leveraged to deliver targeted cancer therapies or vaccines.
Bacterial cancer therapies are being developed to boost existing treatments like immunotherapy and chemotherapy.
While early human trials indicate general safety, challenges remain in controlling bacterial dosage, preventing harmful evolution, and managing potential over-inflammation.
The development of these 'living medicines' could represent a shift from static drugs to adaptive biological systems for cancer treatment.
- Who
- Australian scientists and researchers
- What
- Researching the use of genetically engineered bacteria as 'living medicines' to target and treat cancer cells.
- When
- Ongoing research with accelerated growth in the past five years; early human trials have shown general safety.
- Where
- Australia (implied by authors' affiliations), with research and clinical trials potentially occurring globally.
- Why
- To overcome limitations of current cancer treatments such as drug resistance, poor tumor penetration, and immune suppression, by leveraging bacteria's natural ability to target tumors and stimulate immune responses.
Potential Benefits of Bacterial Cancer Therapy
Challenges and Risks in Bacterial Cancer Therapy
Tumor Targeting and Treatment Delivery
Potential Benefits of Bacterial Cancer Therapy
Certain bacteria naturally target and grow within solid tumors, leaving healthy tissue largely unaffected, and can serve as delivery couriers for targeted therapies.
Challenges and Risks in Bacterial Cancer Therapy
Tumors can suppress the immune system or develop resistance, making them difficult to treat. Bacteria can also evolve unpredictably, posing safety concerns and requiring strict controls.
Immune System Activation and Therapeutic Applications
Potential Benefits of Bacterial Cancer Therapy
Bacteria can activate the body's immune system to attack cancer cells, and engineered bacteria can deliver cancer vaccines or boost existing treatments like immunotherapy and chemotherapy.
Challenges and Risks in Bacterial Cancer Therapy
Many bacterial cancer vaccine trials have not shown superiority over current treatments. There is also a risk of triggering dangerous over-inflammation or excessive immune responses that are difficult to regulate.
Development and Safety of 'Living Medicines'
Potential Benefits of Bacterial Cancer Therapy
Researchers can reprogram bacteria to sense, compute, respond to signals, and deliver cancer-killing molecules, with probiotic species also being candidates for engineering into 'living medicines'.
Challenges and Risks in Bacterial Cancer Therapy
Finding the right dosage is a delicate balance, and even modified bacteria can cause infection or trigger excessive inflammation. 'Biocontainment' strategies are being developed to prevent spread and ensure self-destruction after treatment.
- Historical Observation
- Over a century ago, surgeons noted cancer remission in patients with bacterial infections.
- Current Clinical Use
- A weakened form of Mycobacterium bovis is used to treat bladder cancer by stimulating an immune response.
- Research Activity
- Over 500 research papers, 70 clinical trials, and 24 startup companies have focused on bacterial cancer therapy in the last 30 years, with growth accelerating in the past five years.
- Prominent Bacteria in Trials
- Listeria monocytogenes is being used in over 30 cancer vaccine clinical trials.
- Combination Therapies
- Nearly half of current bacterial cancer therapy trials combine bacteria with immunotherapy or chemotherapy.
- Potential Probiotic Species
- Escherichia coli Nissle, Lactobacillus, and Bifidobacterium are candidates for engineering into 'living medicines'.
- Safety and Control
- Early human trials show general safety, but challenges include finding the right dose, controlling bacterial evolution, and preventing infection or excessive inflammation.